Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 4Unknown 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Other solid neoplasm 2Lymphoid 2Head & Neck 2Dermatologic 2Breast 2Other hematologic neoplasm 1Gynecologic 1CNS 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 139Rituximab 115Etoposide 77Vincristine 75Doxorubicin 62Cytarabine 61Dexamethasone 58Prednisone 55fludarabine 52Methotrexate 46N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 42Lenalidomide 37Gemcitabine 35Radiotherapy 29Melphalan 27pegaspargase 22Prednisolone 22Ifosfamide 22fludarabine phosphate 20Busulfan 20Cisplatin 19Bendamustine Hydrochloride 19Asparaginase 18Peripheral Blood Stem Cell Transplantation 17ibrutinib 16Decitabine 16Carmustine 16Mercaptopurine 15Filgrastim 15Oxaliplatin 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × avelumab × Lymphoid × Clear all
NCT03617666 2023-12-12

AVENuE

University College, London

Phase 2 Unknown
49 enrolled
Lymphoid

Hodgkin Disease

NCT03439501 2021-09-24

Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]

Samsung Medical Center

Phase 2 Unknown
21 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡